Clinical trials: Covid19 Vaccination
Coronavirus Disease (COVID-19)
Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination
This study is a long-term follow-up survey of Japanese people after their second vaccination with the Moderna COVID-19 vaccine. The study sponsor will not be involved in how the participants are treated but will provide…
- Trial name
- NCT04941144
- Testing
- COVID-19 Vaccine
- Where
- Japan
- Volunteers
- 8,538 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19, Pregnancy Related
Evaluation of Humoral Immunity Following COVID-19 in Pregnancy
The proposed study is designed to investigate if and how pregnant women infected with Coronavirus Disease-19 (COVID-19) infection go on to develop long-term immunity.
- Conditions
- COVID-19, Pregnancy Related, Influenza, Human
- Trial name
- ImmunoCOVID (NCT04568044)
- Testing
- Blood sample
- Where
- 2 sites in United Kingdom
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Imperial College London
COVID-19 Vaccines
COVID-19 Booster Dose Reminder/Recall for Adolescents
A single COVID-19 booster dose has been recommended in the United States for adolescents aged ≥12 years to enhance protection against SARS-CoV-2 infection.
- Trial name
- AIMED COVID (NCT05571657)
- Testing
- Reminder/Recall Sent Via Preferred Method of Communication
- Where
- United States
- Volunteers
- 4,304 people
- Sponsor
- Marshfield Clinic Research Foundation
Covid19
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04563702
- Testing
- VXA-CoV2-1
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vaxart
COVID-19
Improving COVID-19 Vaccine Uptake Among Black and Latino Youth
Black and Latino youth may be less likely to get the COVID-19 vaccine than White youth. In this study we will work with community members to come up with ways to help Black and Latino families learn more about the COVID-19…
- Trial name
- NCT05293392
- Testing
- Culturally-Tailored COVID-19 Vaccine Uptake Intervention, Standard Care
- Where
- United States
- Volunteers
- 5,792 people
- Sponsor
- Nemours Children's Health System
Covid19
Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose
CombiVacS is a phase 2 randomized, adaptive trial developed to evaluate the immunogenicity of a dose of COMIRNATY after a previous single dose of VAXZEVRIA.
- Trial name
- CombiVacS (NCT05378191)
- Testing
- COMIRNATY
- Where
- 5 sites in Spain
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
COVID-19 Vaccination
Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): Its' Correlation Factors and an Educational Intervention Programme
The COVID-19 pandemic has spread to over 200 countries worldwide and is still on the rise in 88 countries. Unfortunately, Malaysia is not the exception and registered 340,642 COVID-19 cases till 29 March 2021 since the outbreak…
- Trial name
- NCT04930185
- Testing
- Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme
- Where
- Malaysia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sunway University
COVID-19 Pandemic
The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine
It is a Single Arm, Open Label Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of V-01-351/V-01D Bivalence Vaccine in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of…
- Trial name
- Omicron (NCT05273528)
- Testing
- Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19, Liver Disease
Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)
COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal.
- Conditions
- COVID-19, Liver Disease, Vaccine Reaction
- Trial name
- NCT04883177
- Where
- 37 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
COVID-19
COVID Booster in Pregnancy and Lactation
This is a prospective longitudinal cohort study to evaluate the impact of COVID-19 vaccination and booster on maternal and infant immunity against COVID-19 variants over time.
- Trial name
- NCT05543993
- Testing
- Bivalent COVID-19 Booster
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
COVID-19
A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
The Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) developed by WestVac Biopharma Co., Ltd. is a monovalent modified vaccine designed against Omicron XBB.1.5.
- Trial name
- NCT06175494
- Testing
- Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell), Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
- Where
- China
- Volunteers
- 4,800 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Vaccination; Infection, COVID-19
Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly
Respiratory tract infections, e.g. caused by SARS-CoV-2, disproportionately affect elderly. Vaccination has shown to be the most cost-effective approach to prevent infections.
- Trial name
- HVaNa (NCT05977127)
- Testing
- Comirnaty
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
SARS-CoV-2 Vaccination, Liver Transplantation
Effect of SARS-CoV-2 Vaccination in Liver Transplant Recipients
To investigate the variations in the humoral response to vaccines for the prevention of COVID-19 in liver transplant patients based on the type of immunosuppressive therapy adopted (tacrolimus based vs no-tacrolimus based) and…
- Trial name
- NCT05490342
- Testing
- Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.
- Where
- Italy
- Volunteers
- 61 people
- Sponsor
- University of Rome Tor Vergata
COVID19, Influenza Vaccination
Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares…
- Conditions
- COVID19, Influenza Vaccination, ACE Inhibitors, ARB
- Trial name
- NCT04367883
- Testing
- Antihistamine, Amantadine, ACEI
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Consorci Sanitari de Terrassa
Vaccination, Covid19
The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions
Uptake of vaccination against COVID-19 is key to controlling the pandemic. However, a significant proportion of people report that they do not intend to have a vaccine, often because of concerns they have about its side effects…
- Trial name
- NCT04813770
- Testing
- Theory-based messages, General messages
- Where
- United Kingdom
- Volunteers
- 1,113 people, healthy volunteers welcome
- Sponsor
- University of Glasgow
Preference, Patient
Preferences of Vaccination for COVID-19 Among University Students and Staff: A Discrete Choice Experiment
From March 2021, COVID-19 vaccines have been made available to Hong Kong residents, first to priority groups including healthcare professionals and the elderly, and later to all adults and adolescents.
- Trial name
- NCT05150769
- Where
- Hong Kong
- Volunteers
- 3,423 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
CORONAVIRUS INFECTIONS
Effect of a Vaccination Against COVID-19 on Monocyte Production of Oxygenated Derivatives.
Knowing that the vaccine antigen includes the ACE2 binding moiety (RBD), the hypothesis is that circulating vaccine antigen could reduce the enzymatic activity of ACE2, and thus increase circulating AngII concentration, monocyte…
- Trial name
- VACTICOV2 (NCT05655351)
- Testing
- anti-SARS-Cov-2 vaccination
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
SARS-CoV 2
Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare With Regard to Vaccinations
To investigate the incidence of SARS-CoV-2 infections after vaccination, to monitor the development of SARS-CoV-2 antibody levels after vaccination and to compare this in relation to both previous health \& disease, previous…
- Trial name
- NCT04853004
- Testing
- SARS-CoV2 antibody measurement
- Where
- Sweden
- Volunteers
- 10,000 people
- Sponsor
- Karolinska Institutet
SARS CoV 2 Infection
A Phase IV Vaccine Study Under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2 (COVID-19) Vaccines.
A phase IV study to assess if the SARS-CoV-2 vaccine from Johnson \& Johnson/Janssen (J\&J) results in change in number and activation of platelets and anti-PF4 Level.
- Trial name
- NCT06360744
- Testing
- Johnson & Johnson
- Where
- 5 sites in Denmark
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Jens D Lundgren, MD
SARS-CoV-2
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
The goal of this study is to confirm the onset status of hypersensitivity reactions including shock and anaphylaxis observed after vaccination with this drug in persons with underlying diseases who are considered to have a high…
- Trial name
- NCT05894499
- Where
- Japan
- Volunteers
- 13,309 people
- Sponsor
- ModernaTX, Inc.